期刊
CURRENT DIABETES REPORTS
卷 21, 期 9, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-021-01396-2
关键词
Anti-VEGF; Proliferative diabetic retinopathy; Vitreous hemorrhage; Traction retinal detachment; Panretinal photocoagulation
资金
- Research to Prevent Blindness
Diabetes can result in severe visual loss due to various mechanisms, but advances in treatment including anti-VEGF medications and modern surgical techniques have led to improved outcomes for patients with diabetic retinopathy. Further research is needed to determine the most effective delivery method and timing for treatment.
Purpose of Review Diabetes can be associated with profound visual loss due to several mechanisms. As the duration of diabetes and blood glucose levels increase, these changes become more severe. The proliferation of new blood vessels, vitreous hemorrhage, and tractional retinal detachments may ultimately result and can be devastating to visual function. New advances, including anti-vascular endothelial growth factor (VEGF) medications and innovative microsurgical instruments, have provided additional methods for the management of diabetic retinopathy in the clinic and in the operating room, leading to improved outcomes. Recent Findings Advances in earlier treatment of proliferative diabetic retinopathy, especially with anti-VEGF injections, allow for a reduction in severity, improved vision, and more controlled and successful surgery. Modern surgical techniques and instrumentation have also allowed for improved patient outcomes. Future research into sustained delivery and release of anti-VEGF, reducing the need for frequent in-office injections, may prove to be additionally beneficial. Over the last decade, anti-VEGF has become an increasingly common treatment modality for the management of proliferative diabetic retinopathy, vitreous hemorrhages, and tractional retinal detachments. Further research is needed to determine the ideal method of delivery and timing of the treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据